Charter Oak Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Charter Oak Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-150	Closed	-$3K	–	545
2022 Q2	$3K	Hold	150	–	–	﹤0.01%	792
2022 Q1	$6K	Hold	150	–	–	﹤0.01%	722
2021 Q4	$10K	Hold	150	–	–	﹤0.01%	619
2021 Q3	$9K	Hold	150	–	–	﹤0.01%	588
2021 Q2	$7K	Hold	150	–	–	﹤0.01%	621
2021 Q1	$6K	Hold	150	–	–	﹤0.01%	609
2020 Q4	$9K	Buy	+150	New	+$7.32K	﹤0.01%	530

Other funds holding KYMR

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Charter Oak Capital Management's KYMR Position: Q3 2022 in Review

Charter Oak Capital Management sold out of Kymera Therapeutics (KYMR) in Q3 2022, closing a stake of 150 shares — an estimated $3K sold.

Charter Oak Capital Management first reported a position in KYMR in Q4 2020 and held it in 7 quarters. The position peaked at $10K in Q4 2021. 127 funds tracked by Wall St. Rank hold KYMR as of Q3 2022.

Charter Oak Capital Management reported no remaining Kymera Therapeutics position as of Q3 2022 after selling out during the quarter.
Charter Oak Capital Management sold 150 Kymera Therapeutics shares in Q3 2022, an estimated $3K.
Charter Oak Capital Management first reported a position in Kymera Therapeutics in Q4 2020 and held it in 7 quarters.
Charter Oak Capital Management's Kymera Therapeutics position peaked at $10K in Q4 2021.
127 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.